stilbenes has been researched along with Muscular-Dystrophies* in 2 studies
1 trial(s) available for stilbenes and Muscular-Dystrophies
Article | Year |
---|---|
Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study.
Muscular dystrophies (MDs) are inherited disorders characterized by progressive muscle weakness. Previously, we have shown that resveratrol (3,5,4'-trihydroxy-trans-stilbene), an antioxidant and an activator of the protein deacetylase SIRT1, decreases muscular and cardiac oxidative damage and improves pathophysiological conditions in animal MD models. To determine whether resveratrol provides therapeutic benefits to patients with MDs, an open-label, single-arm, phase IIa trial of resveratrol was conducted in 11 patients with Duchenne, Becker or Fukuyama MD. The daily dose of resveratrol was 500 mg/day, which was increased every 8 weeks to 1000 and then 1500 mg/day. Primary outcomes were motor function, evaluated by a motor function measure (MFM) scale, muscular strength, monitored with quantitative muscle testing (QMT), and serum creatine kinase (CK) levels. Adverse effects and tolerability were evaluated as secondary outcomes. Despite the advanced medical conditions of the patients, the mean MFM scores increased significantly from 34.6 to 38.4 after 24 weeks of medication. A twofold increase was found in the mean QMT scores of scapula elevation and shoulder abduction. Mean CK levels decreased considerably by 34%. Diarrhoea and abdominal pain was noted in six and three patients, respectively. Resveratrol may provide some benefit to MD patients. Topics: Adolescent; Adult; Antioxidants; Child; Creatine Kinase; Female; Humans; Japan; Male; Motor Activity; Muscle Strength; Muscle Weakness; Muscular Dystrophies; Resveratrol; Stilbenes; Young Adult | 2020 |
1 other study(ies) available for stilbenes and Muscular-Dystrophies
Article | Year |
---|---|
Histological assessment of SJL/J mice treated with the antioxidants coenzyme Q10 and resveratrol.
The muscular dystrophies (MDs) are genetic disorders of muscle degeneration due to mutations in genes that encode a wide variety of proteins. Dysferlinopathy are characterized by the absence of dysferlin in skeletal muscle and an autosomal recessive mode of inheritance. Both histological and ultrastructural pathology have been well established in dysferlinopathy patients and dysferlin-deficient animal models. To our knowledge the effect of antioxidant supplementation on this level has not been described previously. This article therefore focuses on the histopathology to reveal the effect of antioxidant supplementation. The study aimed to determine, at cellular level, the histopathological changes in the SJL/J mouse model following a 90 day trial with antioxidant supplementation. Markedly reduced inflammatory insult in the more affected quadriceps muscles of animals treated with high doses of CoQ10 and a combination of resveratrol/CoQ10 were observed. The outcome provides evidence that high doses of antioxidant supplementation resulted in decreased dystrophic markers and enhanced tissue integrity at cellular level. Topics: Animals; Antioxidants; Disease Models, Animal; Female; Mice; Muscle, Skeletal; Muscular Dystrophies; Resveratrol; Stilbenes; Ubiquinone | 2011 |